

1 **COHELAN KHOURY & SINGER**
Michael D. Singer (SBN 115301)
2 msinger@ckslaw.com
3 Kristina De La Rosa (SBN 279821)
kdelarosa@ckslaw.com
4 605 C Street, Suite 200
San Diego, CA 92101
5 Telephone: (619) 595-3001/Facsimile: (619) 595-3000
6 Attorneys for Plaintiff Lisa L. Lee, on behalf of herself
7 and all others similarly situated

8 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
9 **COUNTY OF SAN DIEGO**

10 LISA L. LEE, on behalf of herself and all
others similarly situated,

11 Plaintiffs,

12 v.

13 CVS PHARMACY, INC., a Rhode Island
14 Corporation; CVS HEALTH
15 CORPORATION, INC., a Delaware
16 Corporation; and DOES 1 through 100,
17 inclusive,

18 Defendants.

Case No.

**CLASS ACTION COMPLAINT FOR
DAMAGES, RESTITUTION AND/OR
INJUNCTIVE/DECLARATORY RELIEF**

1. **VIOLATIONS OF THE CARTWRIGHT
ACT [Cal. Bus. & Prof. Code §§ 16720 and
16727]; and**
2. **VIOLATIONS OF CALIFORNIA'S
UNFAIR COMPETITION LAW ("UCL")
[Cal. Bus. & Prof. Code §§ 17200-17208, *et
seq.*]**

DEMAND FOR JURY TRIAL

1 1. Plaintiff LISA L. LEE, brings this civil antitrust and unfair competition class
2 action on behalf of herself, individually, and all others similarly situated against CVS
3 PHARMACY, INC., a Rhode Island Corporation; CVS HEALTH CORPORATION, INC., a
4 Delaware Corporation; and DOES 1 through 100, inclusive (hereinafter referred to as
5 “Defendants” or “CVS”) and hereby complains and alleges as follows based on investigation,
6 information, and belief:

7
8 **I. INTRODUCTION**

9 2. This class action lawsuit involves the unfair, unlawful, and anti-competitive
10 conduct and false representations of Defendants. CVS purposefully misuses its market power to
11 force consumers to purchase opioid overdose reversal medication in order to fill lawfully
12 prescribed and medically necessary prescriptions for pain medication.

13 3. In order to fill a prescription for a medication containing opioids, such as
14 hydrocodone-acetaminophen, CVS forces consumers to simultaneously purchase a prescribed
15 medication, Naloxone or similar drug, designed to rapidly reverse an opioid overdose. The opioid
16 overdose reversal medication can cost more than fifty times the actual opioid pain relief
17 prescription.

18 4. CVS represents to consumers that the concomitant purchase of the overdose
19 reversal medication is required in order for it to fill the opioid prescription. CVS further represents
20 to the consumer that it cannot and will not fill a prescription for opioid medication if a consumer
21 refuses to purchase the expensive overdose reversal medication.

22 5. Defendants’ representations are false. In reality, a pharmacy cannot refuse to fill a
23 lawfully prescribed medication, nor can it impose the requirement to purchase additional
24 medication as a condition for filling an opioid prescription.

25 6. Defendants wield its market power to force consumers to purchase opioid reversal
26 medication at costly prices set by CVS, which not only cause injury to consumers, but also has an
27 anti-competitive effect on the market. As a result of CVS’s action, consumers are foreclosed from
28 the option of purchasing the opioid reversal medication from other pharmacies, including
competitors of Defendants.

1 7. LISA L. LEE (“Plaintiff”) brings this class action against CVS PHARMACY,
2 INC., CVS HEALTH CORPORATION, INC., and DOES 1 through 100, inclusive pursuant to the
3 Cartwright Act, Cal. Bus. & Prof. Code sections 16720, *et seq.* and the Unfair Competition Law
4 (“UCL”), Business & Professions Code sections 17200, *et seq.* to obtain remedies for
5 Defendants’ unlawful, fraudulent, and unfair conduct in misrepresenting and omitting material
6 facts in order to force consumers to purchase medicines they would not choose to purchase from
7 CVS.

8 **II. JURISDICTION AND VENUE**

9 8. Venue as to each Defendant is proper in this judicial district. Code of Civil
10 Procedure section 395. Defendants conduct business and commit violations of the law which
11 have a direct effect on aggrieved consumers and their competitors in San Diego County and
12 California.

13 9. Plaintiff’s claims raise no federal question and are not subject to federal
14 jurisdiction.

15 10. This action is brought under the Cartwright Act, Cal. Bus. & Prof. Code sections
16 16720, *et seq.* and the Unfair Competition Law (“UCL”), Business & Professions Code sections
17 17200, *et seq.* for equitable non-monetary and monetary relief due to Defendants’ unlawful
18 conduct.

19 11. This Court has personal jurisdiction over Defendants because CVS Pharmacy,
20 Inc. and its affiliates do business in the state of California, the claims asserted herein arise from
21 conduct occurring in California.

22 12. Venue is proper in the City and County of San Diego because each Defendant
23 does business in San Diego.

24 13. Venue is further proper in the City and County of San Diego because acts giving
25 rise to the claims asserted herein were committed in the county of San Diego.

26 **III. PARTIES**

27 14. At all times relevant, Lisa L. Lee was and is a natural person over the age of
28 eighteen, residing in California.

1 15. Plaintiff is informed, believes, and alleges Defendant CVS HEALTH
2 CORPORATION is a Delaware Corporation and has conducted business within the state of
3 California.

4 16. Plaintiff is informed, believes, and alleges Defendant CVS PHARMACY, INC. is
5 a Rhode Island Corporation and has conducted business within the state of California. CVS
6 PHARMACY, INC. is a subsidiary of CVS HEALTH CORPORATION.

7 17. The true names and capacities, whether individual, corporate, associate, or
8 otherwise, of Defendants sued as DOES 1 through 100, inclusive, are unknown to Plaintiff, who
9 sues Defendants by fictitious names under Code of Civil Procedure section 474. Plaintiff is
10 informed and believes, and alleges, each DOE Defendant is legally responsible in some manner
11 for the unlawful acts alleged. Plaintiff will seek leave to amend this Complaint to reflect the true
12 names and capacities of DOE Defendants when they become known.

13 18. Plaintiff is informed and believe, and based thereon allege, that each Defendant
14 acted in all respects pertinent to this action as the agent of and/or in concert with the other
15 Defendants, carried out a joint scheme, business plan, or policy in all respects pertinent hereto,
16 and the acts of each Defendant are legally attributable to the other Defendants. Plaintiff is
17 informed and believe that all Defendants are to be jointly and severally liable for the unlawful
18 acts as described herein. Further, Plaintiff is informed and believe, and based thereupon allege,
19 that Defendants, and each of them, each had knowledge and information sufficient to them to
20 have authorized, ratified, and directed the acts of one another as their conduct relates to
21 Defendants' uniform practices and treatment of the proposed Class Members.

22 **IV. GENERAL ALLEGATIONS**

23 19. Defendants describes themselves as a “integrated pharmacy health care
24 company.” CVS HEALTH CORPORATION consists of several business, including more than
25 9,847 CVS retail pharmacies nationwide. Some analysts assert that much of the U.S. population
26 lives within 10-15 minutes of a CVS pharmacy (or within three miles of a CVS pharmacy).

27 20. It would come as no surprise, in light of its ubiquitous locations, that consumers
28 would use CVS pharmacies for medical needs, including to fill medications during time-sensitive

1 and urgent situations or emergencies.

2 21. California Business & Professions Code section 733 prohibits a pharmacy from
3 refusing to fill a prescription drug that has been legally prescribed.

4 22. Specifically, Cal. Bus. & Prof. Code section 733(a) states: “(a) A licentiate shall
5 not obstruct a patient in obtaining a prescription drug or device that has been legally prescribed
6 or ordered for that patient.”

7 23. In January 2019, a law took effect that requires opioid prescribers to also offer
8 prescriptions for opioid-overdose reversal drugs.

9 24. The law requires that a prescriber offer a prescription for a complete or partial
10 reversal of opioid-induced respiratory depression medication; it does not impose a requirement
11 that a patient fill and purchase a prescription for the opioid overdoes medication in order to fill
12 an otherwise lawful prescription.

13 25. Specifically, Cal. Bus. & Prof. Code section 741 states:

14 (a) Notwithstanding any other law, when prescribing an opioid or
15 benzodiazepine medication to a patient, a prescriber shall do the
16 following:

17 (1) Offer the patient a prescription for naloxone hydrochloride or
18 another drug approved by the United States Food and Drug
19 Administration for the complete or partial reversal of opioid-induced
20 respiratory depression when one or more of the following conditions
21 are present:

22 (A) The prescription dosage for the patient is 90 or more morphine
23 milligram equivalents of an opioid medication per day.

24 (B) An opioid medication is prescribed within a year from the date
25 a prescription for benzodiazepine has been dispensed to the patient.

26 (C) The patient presents with an increased risk for opioid overdose,
27 including a patient with a history of opioid overdose, a patient with
28 a history of opioid use disorder, or a patient at risk for returning to
a high dose of opioid medication to which the patient is no longer
tolerant.

29 26. Naloxone is an opioid overdose reversal medication, a medication that works
30 almost immediately to reverse an opioid overdose. Naloxone is currently a prescription drug,
31 but is not a controlled substance. It has few known adverse effects, no potential for abuse, and
32 can be rapidly administered through intramuscular injection or nasal spray. Professional first

1 responders, trained and equipped bystanders such as friends, family, and other non-health care
2 providers (lay people), and drug users themselves can effectively respond and reverse an opioid
3 overdose.

4 27. On or about March 15, 2020, Plaintiff suffered a broken nose. At the emergency
5 room, she was prescribed ten pills of hydrocodone-acetaminophen 10mg-325mg, a painkiller
6 containing an opioid. She was also provided a prescription for Narcan, a brand name for Naloxone.

7 28. She traveled to a CVS Pharmacy near her home to fill her prescription for her pain
8 medication. She informed Defendants that did not want to fill her prescription for Narcan (a brand
9 name for Naloxone). When she filled the prescription (\$0.71 for ten pills), the employee at CVS
10 required her to purchase Narcan nasal spray for \$121.80.

11 29. Defendants told Plaintiff that, legally, Defendants could not fill her prescription for
12 opioid pain medication unless she also filled and purchased the prescription for Narcan.

13 30. Defendants refused to fill Plaintiff's lawfully prescribed prescription for her opioid
14 pain relief medication.

15 31. Plaintiff, who had just left the emergency room and was experiencing significant
16 pain had no choice but to rely on Defendants' representations. She had no meaningful choice but to
17 purchase the Narcan for \$121.80 in order to purchase her pain medications, and therefore incurred
18 actual financial losses due the unlawful conduct of Defendants.

19 32. In order to fill a medication for a medication containing any type of opioid, such as
20 hydrocodone-acetaminophen, CVS maintains a common policy and practice of forcing consumers
21 to simultaneously purchase a medication designed to rapidly reverse an opioid overdose. The
22 opioid reversal medication can cost more than fifty times more than the actual opioid prescription.

23 33. Based on information and belief, Defendants maintain a common practice and
24 policy of representing to their consumers that the concomitant purchase of the overdose reversal
25 medication is required by law. Defendants further represent that CVS cannot and will not fill a
26 prescription for opioid if a consumer refuses to purchase the overdose reversal medication.

27 34. Defendants' representations, made knowingly by CVS, are false. Defendants knew
28 that the representations they made were false and that rather, Defendants were required by law to

1 fill the prescription and could not force consumers, including Plaintiff, to fill a prescription he or
2 she chose not to.

3 35. Defendants wield their market power to force consumers to purchase opioid
4 reversal medication at prices set by CVS which not only cause injury to Plaintiff, but also has an
5 anti-competitive effect on the market. As a result of CVS's action, Plaintiff, and other consumers
6 are foreclosed from the option of purchasing the opioid reversal medication from other pharmacies,
7 including competitors of Defendants.

8 36. This practice is an unlawful tying arrangement in that Defendants used the "tying
9 product" of legally prescribed opioid pain medicines to induce consumers to purchase the "tied
10 product" of Naloxone, or otherwise similar opioid overdose reversal medication.

11 37. On information and belief, Plaintiff believes that Defendants have substantial
12 market power in pain relief medicines to induce the purchase of opioid overdose reversal
13 medications, including Naloxone.

14 38. CVS Pharmacy is the largest U.S. Pharmacy and leads the nation in total
15 Prescription Revenue. In addition to having the largest prescription revenue of any other
16 company, on information and belief, it is believed that it owns over 40% of the market with
17 respect to all pharmaceutical sales in the state of California.

18 39. On information and belief, Plaintiff believes that Defendants have substantial
19 market power, and that they own more than 30% of the market share for pain relief medications
20 containing opioids, including hydrocodone-acetaminophen, throughout the state of California,
21 and including within the county of San Diego.

22 40. The unlawful tying arrangement also caused a substantial amount of sale in the
23 Naloxone and other similar opioid overdose reversal medications, i.e. the "tied product."

24 41. The ultimate effect of this unlawful tying arrangement was to cause substantially
25 lessened competition or tend to create a monopoly in the trade or commerce of pharmaceutical
26 medication, including opioid overdose reversal medications, like Naloxone, in California,
27 including within San Diego.

28 ///

1 42. CVS has a common policy and practice of offering medications with similar
2 terms and provisions as Plaintiff and to other California consumers.

3 43. CVS presented the requirements for purchase of the medications to Plaintiff
4 during times of medical necessity and urgency knowing that Plaintiff would not have any
5 opportunity to investigate the legal adequacy of the terms provided or have a meaningful choice
6 and opportunity to transfer a prescription to another pharmacy.

7 44. A reasonable consumer in a similar situation would not understand at that moment
8 that the representations made by CVS were unlawful. CVS was well aware that consumers,
9 including Plaintiff, would no meaningful choice but to rely on CVS's representations.

10 45. A reasonable consumer would rely on CVS's representations as truth. As a result, a
11 reasonable consumer would be forced to succumb to the unlawful tying arrangement, and purchase
12 the opioid overdose reversal medication in order to obtain pain medication.

13 46. On information and belief, the terms and conditions of the purchase of the
14 medication documents described herein and presented to Plaintiff and other consumers are similar
15 to the terms and conditions offered to all members of the Class. As alleged herein, CVS institutes a
16 common policy and practice of offering tying medications to Plaintiff and other similarly-
17 situated Class Members.

18 **V. CLASS ALLEGATIONS**

19 47. Plaintiff re-alleges and incorporates by reference each and every allegation
20 contained in the preceding paragraphs as though fully set forth.

21 48. Plaintiff and the members of the Class have all suffered an injury in fact as a
22 result of the Defendants' unlawful conduct described herein.

23 49. The "Class Period" means 48 months prior to the filing of the Complaint in this
24 action.

25 50. Plaintiff brings this action on behalf of herself and all other similarly-situated
26 persons as a class action pursuant to California Code of Civil Procedure section 382. The Class
27 Plaintiff seeks to represent is composed of and defined as follows (the "Class"):
28

1 All persons who, within the state of California and within the applicable
2 statute of limitations, purchased opioid medicine from CVS and were
3 required to purchase an opioid overdose reversal medication in order to fill
the opioid medicine prescription.

4 51. Plaintiff reserves the right under California Rules of Court, Rule 3.765(b) to
5 amend or modify the Class to include a broader scope, greater specificity, further division into
6 subclasses, or limitations to particular issues.

7 52. This action is brought and may be maintained as a class action pursuant to Code
8 of Civil Procedure section 382 because there is a well-defined common interest of many persons
9 and it is impractical to bring them all before the court.

10 53. **Ascertainable Class:** The members of the Class are readily ascertainable from
11 Defendants' records of prescriptions issued in the 48 months preceding this filing, and the
12 specific terms and parties identified therein.

13 54. **Numerosity:** The potential quantity of members of the Class as defined is
14 estimated to be at least 1,000 persons and is so numerous that joinder of all members would be
15 unfeasible and impractical. The disposition of their claims through this class action will benefit
16 both the parties and this Court. The quantity of members of the Class is unknown to Plaintiff at
17 this time. However, Plaintiff reasonably estimates the number of pharmacies and the number of
18 members of the Class is greater than 1,000.

19 55. **Typicality:** Plaintiff's claims are typical of the claims of all members of the
20 Class because all members of the Class suffered similar injuries, losses, are owed restitution
21 and/or pecuniary economic damages arising out of Defendants' common course of conduct in
22 violation of law, and the injuries and damages of all members of the Class were caused by
23 Defendants' wrongful conduct in violation of law, as alleged herein.

24 56. **Adequacy:** Plaintiff is an adequate representative of the Class, will fairly protect
25 the interests of the members of the Class, has no interests antagonistic to the members of the
26 Class, and will vigorously pursue this suit via attorneys who are competent, skilled, and
27 experienced in litigating matters of this type. Class Counsel is competent and experienced in
28 litigating class actions and whose attorneys have nearly 100 years of combined experience in

1 handling class action procedures and class action trials.

2 57. **Superiority:** The nature of this action and the nature of laws available to
3 Plaintiff make use of the class action format a particularly efficient and appropriate procedure to
4 afford relief to Plaintiff for the wrongs alleged herein, as follows:

- 5 a. This case involves large corporate Defendants and a sufficient number of
6 Class Members with many relatively small claims and common issues of law
7 and fact;
- 8 b. If each individual member of the Class were required to file an individual
9 lawsuit, the large corporate Defendants would necessarily gain an
10 unconscionable advantage because Defendants would be able to exploit and
11 overwhelm the limited resources of each individual member of the Class with
12 Defendants' superior financial and legal resources;
- 13 c. Proof of a common business practice or factual pattern, of which the
14 members of the Class experienced, is representative of the Class herein and
15 will establish the right of each of the members of the Class to recover on the
16 causes of action alleged herein;
- 17 d. The prosecution of separate actions by the individual members of the Class,
18 even if possible, would create a substantial risk of inconsistent or varying
19 verdicts or adjudications with respect to the individual members of the Class
20 against Defendants; and which would establish potentially incompatible
21 standards of conduct for Defendants; and/or legal determinations with respect
22 to individual members of the Class which would, as a practical matter, be
23 dispositive of the interest of the other members of the Class who are not
24 parties to the adjudications or which would substantially impair or impede
25 the ability of the members of the Class to protect their interests;
- 26 e. The claims of the individual members of the Class are not sufficiently large
27 enough to warrant vigorous individual prosecution considering all of the
28 concomitant costs and expenses attending thereto without aggregation of

1 claims and losses attributed to Defendants' illegal and deceptive conduct;

2 f. Furthermore, as the damages suffered by each individual member of the
3 Class may be relatively small, the expenses and burden of individual
4 litigation would make it difficult or impossible for individual members of the
5 Class to redress the wrongs done to them, while an important public interest
6 will be served by addressing the matter as a class action; and

7 g. The cost to the court system of adjudication of such individualized litigation
8 would be substantial. Individualized litigation would also present the
9 potential for inconsistent or contradictory judgments.

10 **58. Existence and Predominance of Common Questions of Fact and Law:** There
11 are common questions of law and fact as to the members of the Class which predominate over
12 questions affecting only individual members of the Class including, without limitation:

- 13 a. The nature, scope, and operations of the wrongful practices of Defendants;
- 14 b. Whether Defendants engaged in a course of unfair, unlawful, fraudulent,
15 and/or pernicious conduct in their prescription filling practices;
- 16 c. Whether Defendants knew or should have known that their business practices
17 were unfair and/or unlawful;
- 18 d. Whether Defendants owed a duty of care to Plaintiff and the Class;
- 19 e. Whether Defendants' actions were unreasonable and/or violated California
20 law and/or public policy;
- 21 f. Whether Defendants harmed Plaintiff and the Class;
- 22 g. Whether Defendants were unjustly enriched by their unlawful and unfair
23 business practices;
- 24 h. Whether Defendants' sale of medicine constituted an unlawful tying
25 arrangement in violation of the Cartwright Act;
- 26 i. Whether Defendants' have sufficient market power in the sale of opioid
27 medications;
- 28 j. Whether Defendants have effected a substantial amount of the opioid reversal

1 medication;

2 k. Whether Defendants' practice of requiring purchase of an opioid reversal
3 medication in order to purchase a lawfully prescribed opioid medication
4 constituted an unlawful business practice;

5 l. Whether Defendants' false representations in connection with the sale of
6 opioid medications are likely to mislead reasonably prudent consumers
7 acting reasonably under the circumstances;

8 m. Whether Defendants made omissions of material facts;

9 n. Whether Class Members are entitled to damages;

10 o. Whether Class Members are entitled to restitution due to lost profits or
11 diminished sales as a direct and legal result of Defendants' unlawful,
12 deceptive, and/or fraudulent business acts or practices in relation to
13 Defendants' sale of medicine;

14 p. Whether Class Members are entitled to rescind all of their contracts with
15 Defendants;

16 q. Whether Class Members are entitled to injunctive and/or declaratory relief;

17 r. Whether Class Members are entitled to restitution;

18 s. Whether Defendants are liable for pre-judgment interest; and

19 t. Whether Defendants are liable for attorneys' fees and costs.

20 59. **Manageability and Superiority of Class Action Procedure:** The nature of this
21 action and the nature of laws available to Plaintiff make use of the class action format a
22 particularly efficient and appropriate procedure to afford relief to Plaintiff for the wrongs
23 alleged herein. Plaintiff and proposed Class Counsel will obtain necessary consultants,
24 economists, and accountants that can review the books, sales reports, and sales transaction
25 records, and articulate the nature of the claims for restitution, damages, and
26 declaratory/injunctive relief to enjoin Defendants from continuous and ongoing violations of the
27 law.

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

VI. CAUSES OF ACTION
FIRST CAUSE OF ACTION
VIOLATION OF THE CARTWRIGHT ACT, CAL. BUS. & PROF. CODE §§ 16720
and 16727
(AGAINST ALL DEFENDANTS)

60. Plaintiff incorporates the preceding paragraphs of this Complaint.

61. Defendants have continually engaged in an unlawful contracts and agreements in unreasonable restraint of interstate trade and commerce, in violation of the Cartwright Act, including forced and coerced contracts and agreements with consumers requiring them to purchase opioid overdose reversal medication, like Naloxone, in order to purchase lawfully prescribed opioid pain relief medicines.

62. The contracts have consisted of forced agreements with consumers, or unlawful tying arrangements, the substantial terms of which have been to condition the purchase of lawfully prescribed medicine on the purchase of Naloxone, or similar opioid overdose reversal medications.

63. At all times Defendants have had substantial market power to force consumers to purchase Naloxone, or similar opioid overdose reversal medications in order to purchase lawfully prescribed medicine.

64. On information and belief, Plaintiffs believe that Defendants own more than 30% of the market share with respect to opioid prescription pain relief medicines throughout the State of California, including within San Diego County.

65. Consumers are forced to purchase the overdose reversal medications, including Narcan and/or Naloxone, at rates set by Defendants in order to purchase the necessary, and often, time sensitive, opioid prescription pain relief medicine. As a result, consumers are forced to pay higher prices than what they would have otherwise had to.

66. Additionally, the tying arrangements have precluded consumers, including Plaintiff and other members of the Class, from purchasing the product from other businesses, including competitors of CVS.

///

1 67. The ability to purchase prescriptions at other lower-cost non-CVS locations is
2 foreclosed because Plaintiff and consumers are told that this is a necessary purchase.

3 68. The Tied products, i.e., the Naloxone, represented a substantial amount of sales.

4 69. The tying arrangements imposed by Defendants have caused substantial anti-
5 competitive impact.

6 70. On information and belief, the effect of these tied arrangements was to
7 substantially lessen competition or tend to create a monopoly in the sale of opioid prescription
8 medications within California and/or various counties within California, including San Diego
9 County.

10 71. The ability of non-CVS pharmacies to compete effectively with Defendants on
11 the merits have been substantially reduced, limited, and foreclosed by Defendants' tying
12 arrangements, the effect of which was to cause substantially lessened competition.

13 72. As a direct and proximate result of Defendants' actions, Plaintiff has been
14 injured in that she was deprived of the benefits of healthy competition between companies for
15 the aforementioned productions that would have occurred but for Defendant's unlawful and
16 anti-competitive conduct.

17 73. Defendants' actions achieve no legitimate efficiency benefits to counterbalance
18 their demonstrated anticompetitive effects, including the foreclosure of competition.

19 74. As a result of Defendants' violation of the Cartwright Act, Plaintiff and the Class
20 Members have been injured in their business and property in an amount not presently known
21 with precision, which at minimum exceeds the minimum jurisdictional requirements.

22 **SECOND CAUSE OF ACTION**
23 **VIOLATION OF CALIFORNIA UNFAIR COMPETITION LAW, CAL. BUS. & PROF.**
24 **CODE § 17200**
(AGAINST ALL DEFENDANTS)

25 75. Plaintiff incorporates the preceding paragraphs of this Complaint.

26 76. Plaintiff and each Defendant are each "person(s)" as that term is defined by Cal.
27 Bus. & Prof. Code section 17201. Cal. Bus & Prof. Code section 17204 authorizes a private
28 right of action on both an individual and representative basis.

1 77. Cal. Bus. & Prof. Code section 17204, a provision of the Unfair Competition Law
2 (Bus. & Prof. Code sections 17200–17209), confers standing to prosecute actions for relief not
3 only on the public officials named therein, but on private individuals, i.e., “any person acting for
4 the interests of itself, its members or the general public.” Thus, a private Plaintiff who has
5 suffered a financial injury may sue to obtain relief for others.

6 78. “Unfair competition” is defined by Bus. & Prof. Code section 17200 as
7 encompassing several types of business “wrongs,” including: (1) an “unlawful” business act or
8 practice, (2) an “unfair” business act or practice, (3) a “fraudulent” business act or practice, and
9 (4) “unfair, deceptive, untrue or misleading advertising.” The definitions in Section 17200 are
10 drafted in the disjunctive, meaning that each of these “wrongs” operates independently from the
11 others.

12 79. California Business & Professions Code section 17203 provides in pertinent part:

13 Any person who engages, has engaged, or proposes to engage in unfair
14 competition may be enjoined in any court of competent jurisdiction. The
15 court may make such orders or judgments, including the appointment of a
16 receiver, as may be necessary to prevent the use or employment by any
17 person of any practice which constitutes unfair competition, as defined in
18 this chapter, or as may be necessary to restore to any person in interest any
19 money or property, real or personal, which may have been acquired by
20 means of such unfair competition. Any person may pursue representative
21 claims or relief on behalf of others only if the claimant meets the standing
22 requirements of Section 17204 and complies with Section 382 of the Code
23 of Civil Procedure . . .

24 **A. “Unlawful” Prong**

25 80. By knowingly and intentionally tying the purchase of opioid medicines to the
26 purchase of opioid overdose reversal medications and which is prohibited, Defendant CVS has
27 routinely engaged in unlawful business practices.

28 81. Cal. Bus. & Prof. Code section 16727 states:

It shall be unlawful for any person to lease or make a sale or contract for
the sale of goods, merchandise, machinery, supplies, commodities for use
within the State, or to fix a price charged therefor, or discount from, or
rebate upon, such price, on the condition, agreement or understanding that
the lessee or purchaser thereof shall not use or deal in the goods,
merchandise, machinery, supplies, commodities, or services of a
competitor or competitors of the lessor or seller, where the effect of such

1 lease, sale, or contract for sale or such condition, agreement or
2 understanding may be to substantially lessen competition or tend to create
a monopoly in any line of trade or commerce in any section of the State.

3 82. Cal. Civ. Code sections 1572, 1709, and 1710 prohibit the suggestion or
4 assertion of facts which are not true with an intent to alter his position to his injury.

5 83. California Business & Professions Code section 733 prohibits a pharmacy from
6 refusing to fill a prescription drug that has been legally prescribed or legally ordered for that
7 patient.

8 84. Specifically, Cal. Bus. & Prof. Code section 733(a) states: “(a) A licentiate shall
9 not obstruct a patient in obtaining a prescription drug or device that has been legally prescribed
10 or ordered for that patient.”

11 85. Because as alleged herein CVS’s business practices and conduct entailed
12 violations of Cal. Bus & Prof. Code sections 16720 and 16727, and Cal. Civ. Code sections
13 733(a), 1572, 1709, and 1710, Defendants violated California’s Unfair Competition Law, Bus.
14 & Prof. Code sections 17200, *et seq.*, which provide a cause of action for an “unlawful”
15 business act or practice perpetrated on consumers.

16 86. CVS violated Cal. Bus. & Prof. Code sections 17200, *et seq.* through unfair,
17 unlawful, and deceptive business practices. CVS violated California’s Unfair Competition Law,
18 Bus. & Prof. Code sections 17200, *et seq.*, which provide a cause of action for an “unlawful”
19 business acts or practices perpetrated on consumers.

20 87. CVS had other reasonably available alternatives to further its legitimate business
21 interests, other than the conduct described herein, including continuing its massive campaign to
22 coerce consumers to purchase opioid overdose reversal medication.

23 88. Plaintiff suffered actual monetary financial injury in that she was forced to pay
24 money for medication at a cost higher much higher than she would have been but for
25 Defendants’ unlawful and anti-competitive conduct.

26 89. Plaintiff reserves the right to allege further conduct that constitutes other unfair
27 business acts or practices. Such conduct is ongoing and continues to this date.

28 ///

1 **B. “Unfair” Prong**

2 90. CVS’s actions and representations constitute an “unfair” business act or practice
3 under section 17200 in that Defendants’ conduct is substantially injurious to consumers, offends
4 public policy, and is immoral, unethical, oppressive, and unscrupulous as the gravity of the
5 conduct outweighs any alleged benefits attributable to such conduct.

6 91. Without limitation, the business practices describe herein are “unfair” and shock
7 the conscience because they offend established public policy, violate California statutory
8 protections, and are objectively immoral, unethical, unconscionable, oppressive, unscrupulous
9 and/or substantially injurious to consumers in that Defendants’ conduct caused Plaintiff and the
10 Class Members to spend monies.

11 92. At a date presently unknown to Plaintiff, but at least four years prior to the filing
12 of this action, and as set forth above, Defendants committed acts of unfair competition as
13 defined by Cal. Bus. & Prof. Code sections 17200, *et seq.*, as described herein.

14 93. Defendants could and should have furthered their legitimate business interests by
15 not perpetrating fraud on the entire representative class of California borrowers by forcing
16 consumers to purchase items unnecessarily in order to obtain necessary and lawfully prescribed
17 medications. Plaintiff and other members of the Class could not have reasonably avoided the
18 injury suffered by each of them.

19 94. Plaintiff seeks restitution of all amounts expended for the purchase of Naloxone
20 in connection with CVS’s practice of forcing consumers to simultaneously purchase Naloxone or
21 similar drug designed to rapidly reverse an opioid overdose, in order to fill a prescription for a
22 medication containing opioids.

23 95. Plaintiff further seeks a preliminary and permanent injunction prohibiting CVS
24 from continuing its practice of forcing consumers to simultaneously purchase Naloxone, or
25 similar drug designed to rapidly reverse an opioid overdose, in order to fill a prescription for a
26 medication containing opioids.

27 96. Plaintiff reserves the right to allege further conduct that constitutes other unfair
28 business acts or practices. Such conduct is ongoing and continues to this date.

1 **AMENDMENT TO SEEK CLRA RELIEF**

2 97. Should the Defendants not comply with Plaintiff's demand letter pursuant to
3 California Civil Code section 1782, which was mailed on June 26, 2020, Plaintiff intends to
4 amend this Complaint to include a cause of action under the Consumers Legal Remedies Act,
5 including but not necessarily limited to, Cal. Civ. Code sections 1770(a)(2), (3), (5), and (14)-
6 (16).

7 **VII. PRAYER FOR RELIEF**

8 Plaintiff Lisa L. Lee, on behalf of herself and all members of the Class, prays for
9 judgment as follows:

- 10 a. That the Court declare, adjudge, and decree that Defendants have committed the
11 violations of the Cartwright Act and the UCL alleged herein;
- 12 b. That the Court determine that Plaintiff's Cartwright Act and UCL claims may be
13 maintained as a class action pursuant to Cal. Code of Civ. Proc. section 382;
- 14 c. That Defendants, their affiliates, successors, transferees, assignees, and the
15 officers, directors, partners, agents and employees thereof, and all other persons
16 acting or claiming to act on their behalf or in concert with them, be permanently
17 enjoined and restrained from in any manner continuing, maintaining, or renewing
18 the conduct alleged herein, or conduct having a similar purpose or effect; That
19 the Court enter an order enjoining Defendants from continuing to implement its
20 tying arrangements, or contracts or agreements having a similar purpose or effect
21 alleged herein; That the Court enter an order enjoining Defendants from
22 continuing their practice of forcing consumers to simultaneously purchase
23 Naloxone or similar drug, designed to rapidly reverse an opioid overdose, in order
24 to fill a prescription for a medication containing opioids.
- 25 d. That Defendants provide Class Members, in an amount to be proven at trial, to
26 be trebled according to law, plus interest -- including prejudgment interest -- to
27 compensate them for the overcharges they incurred from CVS's violations of
28 California law;

- 1 e. That Defendants provide Class Members with restitution for the overcharges
2 that were extracted by violating the California Cartwright Act, California
3 Business and Professions Code, and the Unfair Competition Law;
- 4 f. An order requiring imposition of a constructive trust and/or disgorgement of
5 Defendants' ill-gotten gains and to pay restitution to Plaintiff and all members of
6 the Class and, also, to restore to Plaintiff and members of the Class all funds
7 acquired by means of any act or practice declared by this court to be an unlawful,
8 fraudulent, or unfair business act or practice, in violation of laws, statutes, or
9 regulations, or constituting unfair competition;
- 10 g. Distribution of any monies recovered on behalf of members of the Class via
11 fluid recovery or *cy pres* recovery where necessary and as applicable, to prevent
12 Defendants from retaining the benefits of their wrongful conduct;
- 13 h. Prejudgment and post judgment interest;
- 14 i. Exemplary and/or punitive damages for intentional misrepresentations pursuant
15 to, *inter alia*, Cal. Civ. Code section 3294;
- 16 j. Costs of this suit;
- 17 k. Reasonable attorneys' fees pursuant to, *inter alia*, California Code of Civil
18 Procedure section 1021.5;
- 19 l. Public injunctive relief prohibiting CVS from future violations of the
20 aforementioned unlawful and unfair practices, pursuant to Cal. Bus. & Prof.
21 Code section 17204; and
- 22 m. Awarding any and all other relief that this Court deems necessary, just,
23 equitable, and proper.

24 ///

25 ///

26 ///

27 ///

28 ///

VIII. DEMAND FOR JURY TRIAL

Plaintiff demands a jury trial of all claims triable as of right by jury.\

Dated: July 2, 2020

COHELAN KHOURY & SINGER

By: 

Michael D. Singer, Esq.

Kristina De La Rosa, Esq.

Attorneys for Plaintiff LISA L. LEE

COHELAN KHOURY & SINGER
605 C Street, Suite 200
San Diego, CA 92101

ClassAction.org

This complaint is part of ClassAction.org's searchable class action lawsuit database and can be found in this post: [CVS Forces Consumers to Buy Overdose Reversal Meds When Filling Opioid-Containing Prescriptions, Class Action Alleges](#)
